학술논문

Spatial repellents: The current roadmap to global recommendation of spatial repellents for public health use.
Document Type
article
Source
Subject
Clinical trials
Cost-effectiveness
Dengue
Malaria
Social science
Spatial repellents
WHO
Infectious Diseases
Rare Diseases
Vector-Borne Diseases
3.2 Interventions to alter physical and biological environmental risks
Prevention of disease and conditions
and promotion of well-being
Infection
Good Health and Well Being
Language
Abstract
Spatial repellent (SR) products are envisioned to complement existing vector control methods through the continual release of volatile active ingredients (AI) providing: (i) protection against day-time and early-evening biting; (ii) protection in enclosed/semi-enclosed and peri-domestic spaces; (iii) various formulations to fit context-specific applications; and (iv) increased coverage over traditional control methods. SR product AIs also have demonstrated effect against insecticide-resistant vectors linked to malaria and Aedes-borne virus (ABV) transmission. Over the past two decades, key stakeholders, including World Health Organization (WHO) representatives, have met to discuss the role of SRs in reducing arthropod-borne diseases based on existing evidence. A key focus has been to establish a critical development path for SRs, including scientific, regulatory and social parameters that would constitute an outline for a SR target product profile, i.e. optimum product characteristics. The principal gap is the lack of epidemiological data demonstrating SR public health impact across a range of different ecological and epidemiological settings, to inform a WHO policy recommendation. Here we describe in brief trials that are designed to fulfill evidence needs for WHO assessment and initial projections of SR cost-effectiveness against malaria and dengue.